Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Filter Content:
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Video & Webinars
Oncology
2 Jun 2015
Nivolumab Extends Survival for Patients With the Most Common Lung Cancer
Findings from a randomised phase III study indicate that PD-1 immunotherapy is an effective treatment option for patients with non-squamous, non-small…
Oncology
2 Jun 2015
An introduction to ASCO 2015 by the 2014-15 president, Peter Paul Yu, MD, FACP, FASCO
Peter Paul Yu, MD, FACP, FASCO introduces ASCO 2015 and the conference themes – how to utilise data, to transform it into learning to impact patient care.
Oncology
21 May 2015
PARP inhibitors and the EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
Oncology
21 May 2015
The mechanisms of BRCA-related breast cancer and molecular profiling
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…
Oncology
21 May 2015
Current research into treatments for BRCA-related breast cancer and the phase 3 EMBRACA trial
Dr Kelly focuses on the phase 3 EMBRACA study, which is evaluating the PARP inhibitor, talazoparib, versus physician’s choice in patients with locally advanced and/or metastatic BRCA-related breast cancer.
Oncology
21 May 2015
The role of BRCA and PARP in DNA repair and BRCA-related breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Peter Fasching (Friedrich-Alexander-Universität Erlangen-Nürnberg…
Oncology
21 May 2015
The phase 3 EMBRACA study of talazoparib in BRCA-related metastatic breast cancer
At the 14th St. Gallen International Breast Cancer Conference 2015, Prof. Dr. med. Michael Untch (HELIOS Klinikum Berlin-Buch, Berlin, Germany) and Prof…
Oncology
12 May 2015
BRCA-related breast cancer: the implications of genetic testing and potential management options
At the 14th St. Gallen International Breast Cancer Conference 2015, Dr Catherine Kelly (Mater Misericordiae University Hospital, Dublin, Ireland) reviews…
Loading posts...
« Previous
1
…
101
102
103
104
105
…
109
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View
